Imaging Mass Cytometry (IMC): Metal-Tagged Multiplexed Imaging

Imaging mass cytometry (IMC) has fundamentally expanded what is measurable in a single tissue section. By labeling antibodies with rare-earth metal isotopes rather than fluorophores and detecting them by mass spectrometry, IMC resolves the protein architecture of tissue at subcellular resolution across 40 or more channels in one acquisition. The technology circumvents the spectral overlap and autofluorescence that constrain fluorescence-based platforms, enabling dense, quantitative protein maps of complex tissues including tumors, immune organs, and archival clinical specimens.

The metal-tag and mass cytometry principle

Mass cytometry uses stable rare-earth metal isotopes as detection labels instead of fluorescent dyes. In the suspension-based form of the technology, single cells are stained with metal-conjugated antibodies, nebulized, and ionized in an inductively coupled plasma before being interrogated one at a time by a TOF mass spectrometer that separates ions by their mass-to-charge ratio. Imaging mass cytometry adapts this core chemistry to intact, sectioned tissue, adding spatial information by coupling the mass spectrometer to a laser ablation unit.

The conceptual advantage over fluorescence imaging is rooted in physics. Fluorescence-based multiplexing is bounded by the emission spectra of available fluorophores: even with computational spectral unmixing, practical panels are constrained to a handful of simultaneous channels before signal bleed-through becomes unmanageable. Metal isotopes, by contrast, each occupy a discrete and non-overlapping position in the mass spectrum. Because rare-earth elements such as lanthanides do not occur in biological tissue at detectable concentrations, every ion signal above background reflects genuine antibody-specific labeling. In the foundational IMC publication by Giesen et al. in Nature Methods, the approach demonstrated simultaneous imaging of 32 proteins and protein modifications at subcellular resolution and projected that the available isotope range could accommodate over 100 markers as reagent libraries continued to expand.

The absence of autofluorescence carries practical significance for archival research. Formalin-fixed, paraffin-embedded (FFPE) tissue generates substantial background fluorescence, particularly from older biobank material, that complicates signal extraction in fluorescence-based methods. Mass-based readout is inherently free of this interference, making decades of archived clinical sections available for highly multiplexed protein-level interrogation without requiring fresh tissue collection.

Laser ablation and acquisition

The IMC workflow encompasses tissue preparation, antibody staining, and instrument acquisition. Tissue sections, typically four to five micrometers (µm) thick, are mounted on standard glass slides and incubated with a panel of metal-conjugated antibodies following protocols adapted from routine immunohistochemistry. After staining and air-drying, the slide loads into the ablation chamber of the Hyperion Imaging System from Standard BioTools.

A UV laser operating at 193 nanometers (nm) scans the tissue in a precise raster pattern. Each laser pulse ablates a 1 µm² area, vaporizing cellular material together with the bound metal-tagged antibodies. The resulting aerosol plume, containing intact metal ions and tissue residues, is transported by a stream of argon gas into the inlet of a CyTOF mass spectrometer. The instrument measures the mass-to-charge ratio of ions from every ablated pixel, identifying which metal isotopes were present and at what abundance. Combining these per-pixel ion counts reconstructs a multi-channel image stack in which each layer represents one marker.

Acquisition runs at 200 hertz (Hz), processing 200 pixels per second. At this rate, imaging 1 mm² takes approximately two hours. Multiple regions of interest (ROIs) can be defined on a single slide, allowing one section to yield several independent image fields or to accommodate a tissue microarray design in which many patient samples appear on the same slide.

The step-by-step acquisition workflow for a standard IMC experiment proceeds as follows:

1. Tissue preparation: Section FFPE or fresh-frozen tissue at four to five µm and mount on a glass slide.
2. Antibody staining: Incubate with the optimized metal-conjugated antibody panel following validated protocols, including antigen retrieval for FFPE material.
3. Air-drying: Allow slides to dry fully before loading; residual moisture disrupts laser ablation efficiency.
4. ROI selection: Use the instrument's preview imaging mode to identify and annotate acquisition regions.
5. Laser ablation: Raster the 193 nm UV laser across each ROI at 200 Hz, ablating 1 µm² of tissue per pulse.
6. Mass detection: Argon gas carries the ablated ion plume to the CyTOF mass spectrometer, which resolves each metal isotope by atomic mass.
7. Image reconstruction: Instrument software assembles per-pixel ion counts into a high-dimensional multi-channel image stack for segmentation and downstream analysis.

Panel design with metal isotopes

The selection of metal isotopes is the central design constraint of an IMC experiment. The most commonly used tags span the lanthanide series, a group of 15 rare-earth elements with atomic masses ranging from 139 to 175 daltons (Da). Commercially available MaxPar metal-conjugated polymer reagents deliver these isotopes in certified, single-isotope form to minimize cross-channel contamination. The panel design considerations summarized in Table 1 reflect practical experience accumulated across published IMC workflows.

Table 1: Panel design considerations for imaging mass cytometry multiplexed tissue imaging.

A practical ceiling of 40 to 50 markers per run reflects reagent purity and sensitivity constraints rather than instrument limitations. The mass spectrometer can resolve more isotopes in principle, but signal detection efficiency varies across the mass range in a pattern specific to each instrument's ion optics, and the available certified single-isotope lanthanide preparations cover a defined mass window. Assigning markers to channels based on antigen abundance and the instrument's empirical mass response curve is therefore standard best practice in IMC panel development. Published IMC panel designs for tumor microenvironment studies typically include immune lineage markers (CD3, CD8, CD20, CD68, and others), cancer cell markers, proliferation indicators such as Ki-67, and structural proteins that anchor cell segmentation.

Antibody validation in IMC follows the same criteria applied in fluorescence-based tissue immunoassays. Because metal-based detection does not improve antibody specificity, a cross-reactive or suboptimally titrated antibody produces spurious signals that confound downstream single-cell analysis equally in both platforms. Panel development therefore includes positive and negative control tissue screening, concentration titration, and, where possible, comparison of staining patterns against independent immunohistochemical references.

Resolution and throughput

IMC operates at a nominal pixel resolution of 1 µm, which approximates the diameter of a cell nucleus in most tissue types. This resolves subcellular protein localization, distinguishing nuclear, cytoplasmic, and membrane compartments, and supports the downstream cell segmentation algorithms on which spatial single-cell analysis depends.

A landmark demonstration of what 40-plus-channel IMC data can reveal at scale comes from the Jackson et al. study published in Nature in 2020. That team simultaneously quantified 35 biomarkers across 720 high-dimensional pathology images of tumor tissue from 352 patients with breast cancer. Spatially resolved single-cell analysis identified phenotypes of tumor and stromal cells, their organization, and their heterogeneity, uncovering novel breast cancer subgroups associated with distinct clinical outcomes. The scope of that experiment, profiling clinical cancer subtypes with long-term survival data, illustrates the translational power that comes from combining IMC's multiplexing depth with preserved tissue architecture.

Throughput remains the technology's most discussed constraint. At 200 Hz and approximately two hours per mm², IMC is substantially slower than cyclic immunofluorescence methods that scan whole tissue slides using widefield optics in minutes. In practice, IMC studies are designed around defined ROIs rather than full-slide imaging, making the choice and placement of those ROIs a critical experimental consideration. The Hyperion XTi system includes an optional slide-loading module supporting up to 40 slides and a real-time preview mode that enables ROI identification without initiating full acquisition, reducing operator time in multi-sample campaigns.

The field has also advanced the resolution ceiling of the platform. High-resolution IMC protocols published in Nature Methods in 2025 demonstrated pixel sizes of 330 nm to 500 nm, achieved by reducing the laser step size and ablation energy to allow multiple rounds of partial tissue ablation. Three-dimensional IMC, described in Nature Cancer in 2022, extended the approach across serial sections to reconstruct volumetric protein maps of breast tumor architecture, resolving cell-level tissue organization and cellular interactions invisible in standard two-dimensional acquisitions.

Advancing Biomarker Discovery With Liquid Biopsy Research

This webinar explores how liquid biopsy research is advancing biomarker discovery through extracellular vesicle (EV)-associated biomarkers and circulating tumor DNA (ctDNA).
View Webinar

Advertisement

IMC vs fluorescence-based multiplexed imaging

IMC and fluorescence-based multiplexed tissue imaging answer the same fundamental question about protein distribution in tissue, but they differ in physical mechanism, practical throughput, and the error modes researchers must manage.

Cyclic fluorescence platforms such as CODEX (co-detection by indexing) and the PhenoCycler system achieve high marker counts through sequential staining and imaging rounds, stripping or quenching fluorescent antibodies between cycles and applying the next set. The approach uses standard fluorescence optics capable of whole-slide imaging at sub-micrometer resolution and at speeds that far exceed IMC per unit area. The trade-offs are autofluorescence management, potential signal accumulation artifacts across many cycles, and image registration error when aligning dozens of sequential acquisitions.

IMC acquires all channels in a single round of laser ablation, eliminating registration artifacts and cyclic staining variability entirely. The key IMC advantages and limitations compared to fluorescence cycling approaches include:

• No spectral overlap: each metal isotope is resolved by atomic mass; crosstalk between channels does not apply
• No autofluorescence: mass-based detection is inherently background-free for biological tissue
• Single-round acquisition: eliminates image misregistration and reduces cumulative staining artifacts
• Lower spatial resolution: 1 µm pixel size versus sub-300 nm resolution available with high-numerical-aperture fluorescence objectives
• Slower acquisition: approximately two hours per mm² versus minutes per slide for widefield fluorescence
• Tissue consumption: laser ablation is destructive; the ablated material cannot be recovered for other assays

For teams navigating the full landscape of spatial proteomics methods, method selection often depends on tissue autofluorescence level, required field of view, panel depth, and available instrumentation rather than any single technical criterion. IMC is particularly productive when working with FFPE archival material, when autofluorescence would compromise fluorescence-based signal, and when deep single-cell phenotyping within defined tissue regions takes priority over whole-slide throughput.

Expanding IMC applications in tissue biology

The tumor microenvironment has driven the majority of published IMC applications. Tumors are spatially heterogeneous structures where the identity, arrangement, and functional state of malignant cells, stromal fibroblasts, endothelial cells, and immune infiltrates collectively shape response to therapy and long-term prognosis. Conventional immunohistochemistry resolves one or at most a small number of markers per section, providing an incomplete view of this ecosystem. IMC's capacity to simultaneously profile 40-plus markers in preserved tissue resolves immune phenotypes, cancer cell states, and stromal composition in a single experiment, as demonstrated in published cancer IMC studies.

Beyond oncology, published studies have applied IMC to characterize immune cell communities within multiple sclerosis lesions, map protein expression gradients in developing tissues, and profile the cellular composition of autoimmune pathology specimens. The technique's compatibility with FFPE sections means that decades of archived clinical samples in pathology biobanks, collected long before IMC existed, are retrospectively accessible for multiplexed protein-level interrogation without requiring new tissue collection. As the spatial biology field builds shared computational frameworks for high-dimensional tissue data, IMC-derived datasets are contributing to mechanistic hypotheses about how spatial protein architecture regulates cell-cell communication, immune evasion, and tissue homeostasis. The combination of depth, spatial resolution, and archival compatibility positions IMC as a durable tool in both discovery research and translational pathology.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.